248 related articles for article (PubMed ID: 16801349)
1. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer.
Sabater L; Bataller L; Carpentier AF; Aguirre-Cruz ML; Saiz A; Benyahia B; Dalmau J; Graus F
J Neurol Neurosurg Psychiatry; 2006 Dec; 77(12):1359-62. PubMed ID: 16801349
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase Cγ antibodies and paraneoplastic cerebellar degeneration.
Höftberger R; Kovacs GG; Sabater L; Nagy P; Racz G; Miquel R; Dalmau J; Graus F
J Neuroimmunol; 2013 Mar; 256(1-2):91-3. PubMed ID: 23273977
[TBL] [Abstract][Full Text] [Related]
3. Paraneoplastic cerebellar degeneration associated with an onconeural antibody against creatine kinase, brain-type.
Tetsuka S; Tominaga K; Ohta E; Kuroiwa K; Sakashita E; Kasashima K; Hamamoto T; Namekawa M; Morita M; Natsui S; Morita T; Tanaka K; Takiyama Y; Nakano I; Endo H
J Neurol Sci; 2013 Dec; 335(1-2):48-57. PubMed ID: 24018129
[TBL] [Abstract][Full Text] [Related]
4. Seronegative paraneoplastic cerebellar degeneration: the PNS Euronetwork experience.
Ducray F; Demarquay G; Graus F; Decullier E; Antoine JC; Giometto B; Psimaras D; Delattre JY; Carpentier AF; Honnorat J
Eur J Neurol; 2014 May; 21(5):731-5. PubMed ID: 24471811
[TBL] [Abstract][Full Text] [Related]
5. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer.
Sabater L; Höftberger R; Boronat A; Saiz A; Dalmau J; Graus F
PLoS One; 2013; 8(3):e60438. PubMed ID: 23536908
[TBL] [Abstract][Full Text] [Related]
6. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.
Shams'ili S; Grefkens J; de Leeuw B; van den Bent M; Hooijkaas H; van der Holt B; Vecht C; Sillevis Smitt P
Brain; 2003 Jun; 126(Pt 6):1409-18. PubMed ID: 12764061
[TBL] [Abstract][Full Text] [Related]
7. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
8. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
Storstein A; Krossnes BK; Vedeler CA
Acta Neurol Scand; 2009 Jul; 120(1):64-7. PubMed ID: 19486326
[TBL] [Abstract][Full Text] [Related]
9. A variant of the anti-Purkinje cell antibody in a patient with paraneoplastic cerebellar degeneration.
Anderson NE; Budde-Steffen C; Wiley RG; Thurman L; Rosenblum MK; Nadeau SE; Posner JB
Neurology; 1988 Jul; 38(7):1018-26. PubMed ID: 3290700
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic cerebellar degeneration associated with anti-protein kinase Cgamma antibodies in a Chinese patient.
Ren H; Zhao D; Xu X; Yang Y; Fan S; Li W; Guan H
J Neuroimmunol; 2020 Sep; 350():577408. PubMed ID: 33217719
[TBL] [Abstract][Full Text] [Related]
11. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer.
Sabater L; Bataller L; Suárez-Calvet M; Saiz A; Dalmau J; Graus F
J Neuroimmunol; 2008 Sep; 201-202():163-5. PubMed ID: 18639938
[TBL] [Abstract][Full Text] [Related]
12. SOX1 antibodies in sera from patients with paraneoplastic neurological syndromes.
Stich O; Klages E; Bischler P; Jarius S; Rasiah C; Voltz R; Rauer S
Acta Neurol Scand; 2012 May; 125(5):326-31. PubMed ID: 21751968
[TBL] [Abstract][Full Text] [Related]
13. Induction of humoral responses specific for paraneoplastic cerebellar degeneration-associated antigen by whole recombinant yeast immunization.
Saiki M; Sakai K; Saiki S; Kitagawa Y; Nakanishi M; Hirose G
J Autoimmun; 2005 May; 24(3):203-8. PubMed ID: 15848042
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Rojas-Marcos I; Picard G; Chinchón D; Gelpi E; Psimaras D; Giometto B; Delattre JY; Honnorat J; Graus F
Neuro Oncol; 2012 Apr; 14(4):506-10. PubMed ID: 22351748
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic cerebellar syndromes associated with antibodies against Purkinje cells.
Schwenkenbecher P; Chacko L; Pul R; Sühs KW; Wegner F; Wurster U; Stangel M; Skripuletz T
Int J Neurosci; 2018 Aug; 128(8):721-728. PubMed ID: 29199513
[TBL] [Abstract][Full Text] [Related]
16. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Schubert M; Panja D; Haugen M; Bramham CR; Vedeler CA
Acta Neuropathol; 2014 Dec; 128(6):835-52. PubMed ID: 25341622
[TBL] [Abstract][Full Text] [Related]
17. Proteasome antibodies in paraneoplastic cerebellar degeneration.
Storstein A; Knudsen A; Vedeler CA
J Neuroimmunol; 2005 Aug; 165(1-2):172-8. PubMed ID: 15964637
[TBL] [Abstract][Full Text] [Related]
18. IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.
Yshii L; Pignolet B; Mauré E; Pierau M; Brunner-Weinzierl M; Hartley O; Bauer J; Liblau R
JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944244
[TBL] [Abstract][Full Text] [Related]
19. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
20. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease.
Bernal F; Shams'ili S; Rojas I; Sanchez-Valle R; Saiz A; Dalmau J; Honnorat J; Sillevis Smitt P; Graus F
Neurology; 2003 Jan; 60(2):230-4. PubMed ID: 12552036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
